---
title: "Daiwa raised the target price of TIGERMED to 45 yuan and reiterated the \"Hold\" recommendation while adjusting the revenue forecast"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277548543.md"
description: "Daiwa's research report indicates that TIGERMED has issued a profit warning, expecting revenue to grow by 1% to 16% in 2025, reaching RMB 6.66 billion to 7.68 billion. Net profit is expected to increase by 105% to 204%, reaching RMB 830 million to 1.23 billion. Revenue in 2026 is expected to grow by 16% to approximately RMB 8 billion, with net profit increasing by 14%. Daiwa has raised its revenue forecast for 2026 to 2027 by 1% to 7%, but lowered its earnings per share forecast by 8% to 12%. The rating is maintained at \"Hold,\" with the target price raised from HKD 38 to HKD 45"
datetime: "2026-03-03T01:56:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277548543.md)
  - [en](https://longbridge.com/en/news/277548543.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277548543.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277548543.md) | [繁體中文](https://longbridge.com/zh-HK/news/277548543.md)


# Daiwa raised the target price of TIGERMED to 45 yuan and reiterated the "Hold" recommendation while adjusting the revenue forecast

Daiwa's research report indicates that TIGERMED (03347.HK) has issued a positive profit alert, expecting a year-on-year revenue growth of 1% to 16% in 2025, reaching RMB 6.66 billion to 7.68 billion (same below), after a decline of 11% in 2024, regaining growth. It is estimated that net profit will increase by 105% to 204% year-on-year, reaching RMB 830 million to 1.23 billion; recurring net profit is expected to decrease by 43% to 61% year-on-year, reaching RMB 330 million to 490 million, mainly due to order cancellations, declining order prices, and increased operating costs related to team expansion.

Looking ahead to 2026, the firm estimates that the company's revenue will grow by 16% year-on-year to approximately RMB 8 billion, with net profit increasing by 14% year-on-year, and net profit margin narrowing by 1 percentage point to 15%.

The firm has raised its revenue forecast for TIGERMED for 2026 to 2027 by 1% to 7%, but lowered the earnings per share forecast for the same period by 8% to 12%, due to a reduction in gross margin and an increase in sales, administrative expenses, and R&D expenses. It maintains a "Hold" rating, with the target price raised from HKD 38 to HKD 45

### 相关股票

- [TIGERMED (03347.HK)](https://longbridge.com/zh-CN/quote/03347.HK.md)

## 相关资讯与研究

- [China Cinda Asset Management FY net profit attributable rmb3,562.3 million](https://longbridge.com/zh-CN/news/281172966.md)
- [Accel Group Revamps Board and Committee Structure for 2026](https://longbridge.com/zh-CN/news/281408484.md)
- [JSW MG Motor sales rise 19% to 6,528 units in March, plans price hikes](https://longbridge.com/zh-CN/news/281308496.md)
- [VAT Group Hit by Q1 Supply Disruptions but Reaffirms Strong 2026 Outlook](https://longbridge.com/zh-CN/news/281125715.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-CN/news/281380835.md)